| Similar Articles |
|---|
 |
The Motley Fool
September 26, 2006
Ralph Casale |
Biotech's Distant Star Cepheid still isn't a profitable company, but strong sales growth should continue. This is a high risk holding until it demonstrates profitability and its instruments are widely adopted.   |
Chemistry World
September 4, 2015
Matthew Gunther |
US regulator reprimands Cepheid for norovirus diagnosis tool quality The US Food and Drug Administration has admonished the molecular diagnostics company Cepheid for failing to maintain good manufacturing practices. |
The Motley Fool
January 26, 2010
Dave Mock |
A Big Upgrade for Cepheid Enough top-performing Motley Fool CAPS members have recently moved to the bull side of Cepheid to upgrade the molecular diagnostics firm from its four-star rank to a top-rated five stars. |
The Motley Fool
November 8, 2007
Brian Orelli |
The 2 Sides of Bio-Rad Results for the third quarter reflect stellar clinical sales combined with mediocre laboratory sales. |
IEEE Spectrum
March 2006
Barry E. DiGregorio |
A Better Anthrax Screener? A newly marketed anthrax detector that originated in the U.S. space program promises to halve the detection time of the system currently used by the U.S. Postal Service. |
The Motley Fool
September 8, 2011
Rex Moore |
Cepheid Seems Solid With These 2 Metrics Cepheid appears to be in good shape in terms of the intangible assets ratio and tangible book value. |
